GlassScriptPhysician profile
Daniel Roger Jones
NPI 1457389264
$6,737.81
in general payments reported to CMS, 2019-2025
49 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $130 · 2021: $780 · 2022: $1,083 · 2023: $1,192 · 2024: $1,471 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $676.42 | 2019-2024 | Qelbree, Qelbree |
| Abbvie INC. | $659.65 | 2019-2025 | |
| Lilly USA, LLC | $614.91 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $562.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $557.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.38 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $324.73 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Astrazeneca Pharmaceuticals LP | $299.81 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $241.92 | 2019-2024 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $173.49 | 2019-2025 | |
| Dexcom, INC. | $157.39 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $152.01 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $147.33 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.51 | 2022-2025 | Caplyta |
| Abbott Laboratories | $128.09 | 2021-2025 | Proclaim, Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.